Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHANCE-3: Colchicine in Acute Ischemic Stroke or TIA
NCT05439356Phase 3Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine in ischemic stroke, Transient Ischemic Attack (TIA), sponsored by Beijing Tiantan Hospital. Started Aug 2022; status: completed.
02
Drugs
colchicine
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT05439356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439356.